Investment analysts at StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN – Get Free Report) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright reissued a “neutral” rating and set a $5.00 target price on shares of Trevena in a research note on Thursday, November 14th.
Check Out Our Latest Stock Analysis on TRVN
Trevena Price Performance
Trevena (NASDAQ:TRVN – Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) EPS for the quarter. The business had revenue of $0.28 million during the quarter. Equities research analysts expect that Trevena will post -23.04 earnings per share for the current fiscal year.
Trevena Company Profile
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
Read More
- Five stocks we like better than Trevena
- What is the S&P 500 and How It is Distinct from Other Indexes
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- How to buy stock: A step-by-step guide for beginners
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- Canada Bond Market Holiday: How to Invest and Trade
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.